Evidence map›Paper›PMID 38910942›Full record

ArticleJournal of Alzheimer's disease reports2024

A Two-Year Observational Study to Evaluate Conversion Rates from High- and Low-Risk Patients with Amnestic Mild Cognitive Impairment to Probable Alzheimer's Disease in a Real-World Setting.

Hyemin Jang, Duk L Na, Jay Cheol Kwon, Na-Yeon Jung, Yeonsil Moon, Jung Seok Lee, Kyung-Won Park, Ae Young Lee, Hanna Cho, Jae-Hong Lee and 6 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of Alzheimer's disease reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03448445 (An Observational Study to Evaluate AD Conversion Rate Differences Between High-risk MCI and Low Risk MCI in Real World Setting), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03448445 completednot on this map

An Observational Study to Evaluate AD Conversion Rate Differences Between High-risk MCI and Low Risk MCI in Real World Setting

TypeobservationalSponsorEisai Korea Inc.Ran2018 to 2021Enrolled201ConditionsMild Cognitive ImpairmentArmsUsual care setting
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Rare extreme polygenic risk scores strongly indicate Alzheimer's disease risk.medRxiv : the preprint server for health sciences · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hyemin JangDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Duk L NaDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jay Cheol KwonDepartment of Neurology, Changwon Fatima Hospital, Changwon, Republic of Korea.
Na-Yeon JungDepartment of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Yeonsil MoonDepartment of Neurology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.
Jung Seok LeeDepartment of Neurology, Jeju National University College of Medicine, Jeju, Republic of Korea.
Kyung-Won ParkDepartment of Neurology, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, Republic of Korea.
Ae Young LeeDepartment of Neurology, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
Hanna ChoDepartment of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jae-Hong LeeDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Byeong C KimDepartment of Neurology, Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea.
Kee Hyung ParkDepartment of Neurology, College of Medicine, Gachon University Gil Hospital, Incheon, Republic of Korea.
Byung-Chul LeeDepartment of Neurology, College of Medicine, Hallym University, Seoul, Republic of Korea.
Hojin ChoiDepartment of Neurology, Hanyang University Guri Hospital, Guri, Republic of Korea.
Jieun KimDepartment of Medical, Eisai Korea Inc., Seoul, Republic of Korea.
Mee Young ParkDepartment of Neurology, Yeungnam University College of Medicine, Daegu, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Predicting conversion to probable Alzheimer&s disease (AD) from amnestic mild cognitive impairment (aMCI) is difficult but important. A nomogram was developed previously for determining the risk of 3-year probable AD conversion in aMCI. Objective: To compare the probable AD conversion rates with cognitive and neurodegenerative changes for 2 years from high- and low risk aMCI groups classified using the nomogram. Methods: This prospective, multicenter, observational study was conducted in Korea. A total of patients were classified as high- or low-risk aMCI according to the nomogram and followed-up for 2 years to compare the annual conversion rate to probable AD and brain structure changes between the two groups. Results: In total, 176 (high-risk, 85; low-risk, 91) and 160 (high-risk, 77; low-risk, 83) patients completed the 1-year and 2-year follow-up, respectively. The probable AD conversion rate was significantly higher in the high-risk (Year 1, 28.9%; Year 2, 46.1%) versus low-risk group (Year 1, 0.0%; Year 2, 4.9%, both p < 0.0001). Mean changes from baseline in Seoul Neuropsychological Screening Battery-Dementia Version, Clinical Dementia Rating-Sum of Box, and Korean version of the Instrumental Activities of Daily Living scores and cortical atrophy index at Years 1 and 2 were significantly greater in the high-risk group (p < 0.0001). Conclusions: The high-risk aMCI group, as determined by the nomogram, had a higher conversion rate to probable AD and faster cognitive decline and neurodegeneration change than the low-risk group. These real-world results have clinical implications that help clinicians in accurately predicting patient outcomes and facilitating early decision-making.Trial Registration: ClinicalTrials.gov (NCT03448445).

Indexed as

Alzheimer’s diseaseamnestic mild cognitive impairmentconversion rateneurodegenerationneuropsychometrynomogram

Identifiers

PMID38910942
PMCPMC11191635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.